Australia Liver Cancer Therapeutics Market Report 2022 to 2030

Australia Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Australia liver cancer therapeutics market will reach a value of $142.3 Mn from $35.2 Mn in 2022, growing at a CAGR of 19.1% during 2022-30. Liver cancer therapeutics in Australia is dominated by a few domestic pharmaceutical companies such as Imugene Limited, Kazia Therapeutics, and Sirtex Medical Limited. Liver cancer therapeutics in Australia is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10AUPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Dr. Vishwa Modhia

Buy Now

Australia Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Australia liver cancer therapeutics market will reach a value of $142.3 Mn from $35.2 Mn in 2022, growing at a CAGR of 19.1% during 2022-2030.

Australia is a high-income developed country in Oceania bordering the Indian Ocean and the Southern Pacific Ocean. In Australia, liver cancer is responsible for 12% of all gastrointestinal malignancies, with alcohol consumption being a contributing factor. According to the most recent WHO data, 2,036 people died from liver cancer in Australia in 2020, accounting for 1.49 % of all deaths. With an age-adjusted death rate of 4.61 per 100,000 population, Australia ranks 112th in the world.

Liver cancer, also known as hepatocellular carcinoma (HCC), is a major health concern in Australia, where it is the sixth most frequent type of cancer. The development and availability of therapies for liver cancer are critical in the prevention and treatment of this disease. Australia's government spent 10.7 % of its GDP on healthcare in 2020.

australia liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

There have been numerous advancements in liver cancer therapies in Australia in recent years. The advent of targeted medicines such as sorafenib and lenvatinib, which have been found to be effective in treating advanced HCC, has been one of the important growth reasons. Furthermore, progress has been made in the development of immunotherapies for liver cancer, with medications like nivolumab and pembrolizumab showing promise in clinical trials. Australia is geographically adjacent to dynamic Asian economies and is an RCEP member. It also enjoys a high level of living, thanks to immigration, which is fuelling population growth and illness prevalence.

Market Restraints

In comparison to other nations, Australia has a very small patient population, which might make large-scale clinical trials and justifying the development of new liver cancer treatments difficult. The topography and population density of Australia can make it difficult for patients to get liver cancer treatments, particularly in rural and remote locations. Australia's economy remains strongly dependent on Chinese spending. The disparities between Australia's federated states are enormous.

Competitive Landscape

Key Players

Imugene Limited - Imugene Limited is an Australian biotechnology company that focuses on the development of immunotherapies for the treatment of cancer, including liver cancer. The company's lead product is HER-Vaxx, a therapeutic cancer vaccine that targets the HER-2/neu receptor
Kazia Therapeutics Limited - Kazia Therapeutics Limited is an Australian biotechnology company that develops and produces a range of medicines, including treatments for brain cancer and other cancers such as liver cancer
Sirtex Medical Limited - Sirtex Medical Limited is an Australian medical device company that develops and produces a range of products for the treatment of liver cancer, including SIR-Spheres Y-90 resin microspheres, a targeted radiation therapy
Patrys Limited - Patrys Limited is an Australian biotechnology company that develops and produces a range of medicines, including treatments for cancer such as liver cancer
CSL Limited - CSL Limited is an Australian multinational biopharmaceutical company that develops and produces a range of medicines, including treatments for cancer such as liver cancer

Recent Notable Updates

September 2022: Sirtex Medical has received favorable approval in Brazil for SIR-Spheres® Y-90 resin microspheres for HCC treatment. ANS supports SIR-Spheres for use in selective internal radiation therapy (SIRT), a minimally invasive treatment that delivers high doses of radiation specifically to malignancies while sparing surrounding healthy liver tissue, in an update to its List of Health Procedures and Events. SIR-Spheres got product approval from the Brazilian Health Regulatory Agency (ANVISA) in 2014.

Healthcare Policies and Reimbursement Scenarios

In Australia, the regulation of liver cancer therapeutics is overseen by the Therapeutic Goods Administration (TGA), which is responsible for evaluating the safety, efficacy, and quality of all medicines, including those used for the treatment of liver cancer. Regarding reimbursement, Australia has a national healthcare system called Medicare that provides coverage for all citizens and permanent residents. Medicare provides coverage for a range of liver cancer therapeutics, including chemotherapy, targeted therapy, and immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Australia Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.